Allergan, Duke Get Generic Lash-Growth Treatments Blocked

Law360, New York (January 30, 2013, 4:39 PM EST) -- A North Carolina federal judge has blocked the release of generic versions of Allergan Inc. and Duke University’s Latisse eyelash growth stimulant, ruling three generics makers had infringed two Allergan and Duke patents.

According to U.S. District Judge Catherine C. Eagles’ Jan. 24 order, Apotex Inc., Sandoz Inc. and Hi-Tech Pharmacal Co. Inc.’s planned generic bimatoprost topical solutions indirectly infringe on two patents for topical solutions meant to stimulate mammalian hair growth — U.S. Patent Numbers 7,351,404 and 7,388,029, both issued in 2008 — and may...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.